UY31494A1 - Formulaciones de soluciones oftalmicas u opticas para uso topico que contienen clorhidrato de moxifloxacina y fosfato de dexametasona - Google Patents

Formulaciones de soluciones oftalmicas u opticas para uso topico que contienen clorhidrato de moxifloxacina y fosfato de dexametasona

Info

Publication number
UY31494A1
UY31494A1 UY31494A UY31494A UY31494A1 UY 31494 A1 UY31494 A1 UY 31494A1 UY 31494 A UY31494 A UY 31494A UY 31494 A UY31494 A UY 31494A UY 31494 A1 UY31494 A1 UY 31494A1
Authority
UY
Uruguay
Prior art keywords
ophthalmic
moxifloxacine
chlorhydrate
formulations
topical use
Prior art date
Application number
UY31494A
Other languages
English (en)
Inventor
D Ph
Michael Wall
Suresh C Dixit
Onkar N Singh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of UY31494A1 publication Critical patent/UY31494A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se describen composiciones de soluciones oftálmicas y opticas moxifloxacina y fosfato de dexametasona para administracion topica.
UY31494A 2007-11-27 2008-11-27 Formulaciones de soluciones oftalmicas u opticas para uso topico que contienen clorhidrato de moxifloxacina y fosfato de dexametasona UY31494A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US99045207P 2007-11-27 2007-11-27

Publications (1)

Publication Number Publication Date
UY31494A1 true UY31494A1 (es) 2009-03-02

Family

ID=40467276

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31494A UY31494A1 (es) 2007-11-27 2008-11-27 Formulaciones de soluciones oftalmicas u opticas para uso topico que contienen clorhidrato de moxifloxacina y fosfato de dexametasona

Country Status (16)

Country Link
US (2) US7888370B2 (es)
EP (1) EP2211835A1 (es)
JP (1) JP2011504881A (es)
KR (1) KR20100090278A (es)
CN (1) CN101861139A (es)
AR (1) AR069438A1 (es)
AU (1) AU2008329876A1 (es)
BR (1) BRPI0819908A2 (es)
CA (1) CA2703913A1 (es)
CL (1) CL2008003536A1 (es)
MX (1) MX2010004953A (es)
RU (1) RU2010126096A (es)
TW (1) TW200932285A (es)
UY (1) UY31494A1 (es)
WO (1) WO2009070530A1 (es)
ZA (1) ZA201002884B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7220431B2 (en) * 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2013065028A1 (en) * 2011-11-04 2013-05-10 Micro Labs Limited Fixed dose combination containing azithromycin and loteprednol for treatment of ocular infections
ITMI20122002A1 (it) * 2012-11-26 2014-05-27 Farmacologico Milanese Srl Lab Preparazioni farmaceutiche liquide stabilizzate
US9968679B2 (en) 2013-01-31 2018-05-15 Senju Pharmaceutical Co., Ltd. Clear aqueous solution
US20160279055A1 (en) 2013-07-22 2016-09-29 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
US20150164882A1 (en) 2013-07-22 2015-06-18 Imprimis Pharmaceuticals, Inc. Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
US10130639B1 (en) * 2015-09-05 2018-11-20 Randal Davis Homogeneous ophthalmic composition
US11452732B2 (en) * 2015-09-05 2022-09-27 Randal Davis Homogeneous ophthalmic composition
GR1008921B (el) * 2015-12-10 2017-01-12 Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον δεξαμεθαζονη
WO2017192675A1 (en) * 2016-05-06 2017-11-09 Imprimis Pharmaceuticals, Inc. Pharmaceutical ophthalmic compositions and methods for fabricating thereof
US20190216830A1 (en) * 2017-10-06 2019-07-18 Aciont Inc. Ophthalmic compositions
CN113750041A (zh) * 2020-06-04 2021-12-07 成都倍特药业股份有限公司 一种地塞米松磷酸钠液体制剂及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2939873A (en) * 1959-01-26 1960-06-07 Merck & Co Inc Synthesis of steroid phosphates
US5414011A (en) * 1987-09-11 1995-05-09 Syntex (U.S.A.) Inc. Preservative system for ophthalmic formulations
US5407926A (en) * 1987-12-29 1995-04-18 Alcon Laboratories, Inc. Ophthalmic composition
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
US5397771A (en) * 1990-05-10 1995-03-14 Bechgaard International Research And Development A/S Pharmaceutical preparation
ZA924953B (en) * 1991-07-25 1993-04-28 Univ Louisville Res Found Method of treating ocular inflammation
ES2079994B1 (es) * 1992-10-07 1996-08-01 Cusi Lab Formulacion farmaceutica a base de polimixina-trimetoprim y un agente antiinflamatorio para su utilizacion topica oftalmica y otica.
US6740664B2 (en) * 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
US6716830B2 (en) * 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
AU2001261748A1 (en) * 2000-05-19 2001-12-03 Alcon Laboratories Inc. Antibiotic compositions for treatment of the eye, ear and nose

Also Published As

Publication number Publication date
TW200932285A (en) 2009-08-01
RU2010126096A (ru) 2012-01-10
EP2211835A1 (en) 2010-08-04
JP2011504881A (ja) 2011-02-17
US20110082125A1 (en) 2011-04-07
US7888370B2 (en) 2011-02-15
MX2010004953A (es) 2010-08-10
CA2703913A1 (en) 2009-06-04
KR20100090278A (ko) 2010-08-13
CN101861139A (zh) 2010-10-13
US20090137539A1 (en) 2009-05-28
AR069438A1 (es) 2010-01-20
BRPI0819908A2 (pt) 2015-05-19
CL2008003536A1 (es) 2009-10-16
AU2008329876A1 (en) 2009-06-04
US8173671B2 (en) 2012-05-08
ZA201002884B (en) 2011-07-27
WO2009070530A1 (en) 2009-06-04

Similar Documents

Publication Publication Date Title
UY31494A1 (es) Formulaciones de soluciones oftalmicas u opticas para uso topico que contienen clorhidrato de moxifloxacina y fosfato de dexametasona
UY32203A (es) Amino pirimidinas y su uso en terapia
UY30327A1 (es) Nuevos compuestos ii
UY30942A1 (es) Nuevos derivados de 3-([1,2,4,]triazolo[4,3-a]piridin-7-il)benzamida
UY29238A1 (es) Formulaciones de nepafenac para su administracion topica
UY31456A1 (es) Derivados de 2-pirazinona como inhibidores de la elastasa de los neutrofilos
NI201000055A (es) 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa.
CL2013000304A1 (es) Compuestos derivados de 2-arilamino-bencimidazoles inhibidores de prostaglandina e2 (mpges-1); composicion farmaceutica que los comprende; compuestos intermediarios; uso en el tratamiento de enfermedades inflamatorias y/o afecciones asociadas, en particular el dolor.
CR11857A (es) Compuestos pirazolicos 436
NI201200184A (es) Morfolinopirimidinas y su uso en terapia
UY31481A1 (es) Nuevos derivados de pirimidina, procesos de preparacion, composiciones farmacéuticas conteniéndolos y aplicaciones
UY30748A1 (es) Compuesto0s novedosos
ECSP099250A (es) USO DE 2-6-(3-amino-piperidin-1-Il)-3-metil-2,4-dioxo-3,4-dihIdro-2H-pIrimidin-1-IlmetIL-4-fluoro-benzonitrilo
ECSP10010548A (es) Composiciones y metodos de preparacion y uso de las mismas
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
CO6331427A2 (es) Inhibodores de beta -lactamasa
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
BRPI0915084B8 (pt) composto, e, composição farmacêutica
GT200900192A (es) Derivados de imidazol como inhibidores de proteina de uso de cinesina (eg-5).-
BRPI0921699A2 (pt) complexo antioxidante, composicoes cosmeticas e farmaceutica contendo o referido complexo e uso deste complexo
UY33201A (es) Compuestos de pirazol como antagonistas de crth2.
UY30195A1 (es) Derivados de fenetanolamina, procedimiento de preparacion, composiciones que los contienen y aplicaciones
CR11065A (es) Administracion semanal de inhibidores de peptidasa de dipeptidilo
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
HN2011002578A (es) Nuevos derivados de compuestos de [3,2-c]pirazol esteroidal con actividad clucocorticoide.

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20200812